OAOlga Atochina

Olga Atochina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga Atochina has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Donald Harn

    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA

    2 shared publications
  • Akram A. Da’dAra

    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA

    1 shared publication
  • Danuta Piskorska

    Neose Technologies , Horsham, PA 19044

    1 shared publication
  • Donald A Harn

    Department of Immunology and Infectious Diseases, Harvard School of Public Health , Boston, MA 02115

    1 shared publication
  • Donald A. Harn

    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA

    1 shared publication
  • Edward McGuire

    Neose Technologies , Horsham, PA 19044

    1 shared publication

Latest Publications

  • Open Access

    The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo

    by Olga Atochina, Akram A. Da’dAra, Mirjam Walker, Donald A. Harn

    Summary: The early pathogen–macrophage interactions that help drive macrophage maturation towards classically or alternatively activated are largely unknown. To examine this question we utilized the immunomodulatory glycan Lacto‐N‐fucopentaose III (LNFPIII), which contains the Lewis X (LeX) trisaccharide, to activate murine peritoneal macrophages in vivo. Because LNFPIII is known to induce anti‐inflammatory responses, we asked if LNFPIII stimulation of macrophages in vivo initiates alternative activation events such as upregulation of Arginase 1, Ym1, FIZZ‐1, MGL‐1 or macrophage mannose receptor (MMR). Examination of peritoneal exudate cells from mice 20 hr post‐LNFPIII injection demonstrated increased Arginase 1 activity, at the mRNA and protein levels, coincident with undetectable inducible nitric oxide synthase expression or nitric oxide production. In addition to Arginase 1, Ym1 expression was also significantly upregulated at 20 and 48 hr after LNFPIII exposure in vivo. However, the expression of FIZZ‐1, MGL‐1, and MMR was not changed in these macrophages. In an attempt to determine activation requirements for functional activity, we adoptively transferred antigen‐pulsed, in vivo LNFPIII activated macrophages into naïve recipients and found that they were capable of triggering recipient T cells to secrete elevated levels of interleukin (IL)‐10 and IL‐13 compared to mice receiving control macrophages. Together, these data demonstrate that upregulation of expression of Arginase 1 and Ym1 occur very early in activation of macrophages, and can be independent of other alternatively activated (AA) macrophage markers. Importantly, these early events appear to be IL‐4/IL‐13‐independent in our model. In the future we hope to determine if upregulation of these initial AA maturational events is sufficient for these macrophages to exert immunoregulatory activity in vivo.


  • Prevention of psoriasis‐like lesions development in fsn/fsn mice by helminth glycans

    by Olga Atochina, Donald Harn

    Abstract:  The helminth glycan LNFPIII is an immunomodulatory molecule, driving CD4+ Th2‐type biasing as well as immune suppression. Psoriasis is an autoimmune disease where the immune mechanisms as well as the antigens responsible for development of immune autoreactivity are still not known. In the absence of defined immunological mechanisms, we asked whether LNFPIII would function as novel therapy for psoriasis. We tested the therapeutic efficacy of LNFPIII using the flaky skin (fsn)/fsn mutant mouse model of psoriasis‐like lesion development. We found that treatment of mice with LNFPIII prevented the appearance of psoriatic skin lesions on fsn/fsn mice. Examination of the skin 2 weeks after treatment demonstrated that prevention of skin lesions was associated with maintenance of normal epidermis thickness in LNFPIII‐treated mice as compared with a significantly thickened epidermis in control treated and diseased mice. In addition, cells from skin of LNFPIII‐treated mice produced lower amounts of interferon‐γ as compared with cells from skin of control treated diseased mice. Examination of macrophages and T cells from peripheral lymph nodes of control and LNFPIII‐treated fsn/fsn mice showed that glycan treatment reduced the numbers of Gr1+F4/80+ macrophages and the numbers of CD8+ T cells, restoring the numbers of these two cell populations as well as the CD4 : CD8 ratio to near normal levels. Overall, the results from this study suggest that the helminth immunomodulatory glycan LNFPIII functions to prevent development of psoriatic‐like skin lesions in fsn/fsn mice.


  • LNFPIII/LeX-Stimulated Macrophages Activate Natural Killer Cells via CD40-CD40L Interaction

    by Olga Atochina, Donald Harn

    Lacto-N-fucopentaose III (LNFPIII) is a human milk sugar containing the biologically active Lewis X (LeX) trisaccharide. LNFPIII/LeX is also expressed by immunosuppressive helminth parasites, by bacteria, and on a number of tumor/cancer cells. In this report, we first demonstrate that LNFPIII activates macrophages in vitro as indicated by upregulation of Gr-1 expression on F4/80+cells. Further, we investigated the effect of LNFPIII-activated macrophages on NK cell activity. We found that LNFPIII-stimulated F4/80+cells were able to activate NK cells, inducing upregulation of CD69 expression and gamma interferon (IFN-γ) production. The experiments show that NK cell activation is macrophage dependent, since NK cells alone did not secrete IFN-γ in response to LNFPIII. Furthermore, we found that activation of NK cells by glycan-stimulated macrophages required cell-cell contact. As part of the cell-cell contact mechanism, we determined that CD40-CD40L interaction was critical for IFN-γ secretion by NK cells, as the addition of anti-CD40L antibodies to the coculture blocked IFN-γ production. We also demonstrated that LNFPIII-stimulated macrophages secrete prostaglandin E2, interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF-α) but a very low level of IL-12. Interestingly, addition of anti-TNF-α, anti-IL-10, or anti-IL-12 monoclonal antibodies did not significantly alter NK cell activity. Our data show that these soluble mediators are not critical for LNFPIII-stimulated macrophage activation of NK cells and provide further evidence for the importance of cell-cell contact and CD40-CD40L interactions between macrophages and NK cells.


  • A Schistosome-Expressed Immunomodulatory Glycoconjugate Expands Peritoneal Gr1+ Macrophages That Suppress Naive CD4+ T Cell Proliferation Via an IFN-γ and Nitric Oxide-Dependent Mechanism

    by Olga Atochina, Toby Daly-Engel, Danuta Piskorska, Edward McGuire, Donald A Harn

    Lacto-N-fucopentaose III (LNFPIII) is found in human milk and on the Th2 driving helminth parasite Schistosoma mansoni. This pentasaccharide drives Th2-type responses in vivo and in vitro when conjugated to a carrier. In an attempt to further understand early events in Th1 to Th2 switching, we examined phenotypic and functional changes in peritoneal cell populations in BALB/c and SCID mice following LNFPIII-dextran injection. We found that i.p. injection with LNFPIII-dextran resulted in rapid (<20 h) expansion of the Gr1+ subpopulation of F4/80+/CD11b+ peritoneal cells, comprising up to 75% of F4/80+/CD11b+ peritoneal cells compared with 18% in uninjected or dextran-injected mice. Functionally, these cells suppressed anti-CD3- and anti-CD28-induced proliferation of naive CD4+ T cells. LNFPIII-dextran also expanded functional Gr1+ suppressor macrophages in SCID mice, demonstrating that expansion and function of suppressor cells did not require T cells. Suppression in both BALB/c and SCID mice was NO and IFN-γ dependent, as addition of inhibitors of inducible NO synthase (NG-monomethyl-l-arginine), as well as anti-IFN-γ Abs, restored the ability of CD4+ T cells to proliferate in vitro. Depletion of the F4/80+ subset of Gr1+ cells eliminated the suppressive activity of peritoneal exudate cells showing that these cells were macrophages. Thus, LNFPIII-dextran rapidly expands the Gr1+ suppressor macrophage population in the peritoneal cavities of otherwise naive mice. These Gr1+ cells suppress proliferation of naive CD4+ T cells in an NO-dependent mechanism, and may play a regulatory role in the switching of Th1- to Th2-type responses.